FAKTOR-OPTIONSSCHEIN - GILEAD SCIENCES | Delayed Deutsche Boerse AG 14:22:30 2024-06-13 EDT | ||
| 2.45 EUR | 0.00% |
|
| Current month | -0.81% | ||
| 1 month | -19.14% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GILEAD SCIENCES, INC.
Latest news about GILEAD SCIENCES, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-06-13 | 2.45 | 0.00% |
| 24-06-12 | 2.45 | -5.77% |
| 24-06-11 | 2.6 | -3.35% |
| 24-06-10 | 2.69 | +3.07% |
| 24-06-07 | 2.61 | +8.30% |
Delayed Quote Deutsche Boerse AG
Last update June 13, 2024 at 02:22 pm
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | GILEAD SCIENCES, INC. |
| Issuer | 
Société Générale
|
| WKN | SH2SAR |
| ISIN | DE000SH2SAR2 |
| Date issued | 2022-02-14 |
| Strike | 61.8 $ |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 10.04 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 39.2 € |
|---|---|
| Lowest since issue | 2.12 € |
| Spread | 0.01 € |
| Spread % | 0.40% |
Company Profile
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
-
Consensus: Gilead Sciences, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
64.34
USD
Average target price
82.7
USD
Spread / Average Target
+28.53%
- Stock Market
- Certificates
- Certificat
